Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
APLS closed up 3.2 percent on Friday, March 23, 2018, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical APLS trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 23||NR7||Range Contraction||0.00%|
|Mar 23||Wide Bands||Range Expansion||0.00%|
|Mar 22||1,2,3 Pullback Bullish||Bullish Swing Setup||3.20%|
|Mar 22||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||3.20%|
|Mar 22||Spinning Top||Other||3.20%|
|Mar 22||Wide Bands||Range Expansion||3.20%|
|Mar 21||NR7||Range Contraction||5.20%|
|Mar 21||Inside Day||Range Contraction||5.20%|
|Mar 21||Wide Bands||Range Expansion||5.20%|
|Mar 21||Down 3 Days in a Row||Weakness||5.20%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more APLS news...
|52 Week High||27.53|
|52 Week Low||12.45|
|200-Day Moving Average||0.0|
|50-Day Moving Average||18.9462|
|20-Day Moving Average||22.4005|
|10-Day Moving Average||24.343|
|Average True Range||1.8737|
|Chandelier Exit (Long, 3 ATRs )||21.9089|
|Chandelier Exit (Short, 3 ATRs )||20.4211|
|Upper Bollinger Band||27.2145|
|Lower Bollinger Band||17.5865|
|Percent B (%b)||0.72|
|MACD Signal Line||1.846|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||25.93|
|Resistance 3 (R3)||25.92||25.43||25.69|
|Resistance 2 (R2)||25.43||25.07||25.44||25.61|
|Resistance 1 (R1)||24.97||24.85||25.20||24.98||25.53|
|Support 1 (S1)||24.02||24.12||24.25||24.03||23.47|
|Support 2 (S2)||23.53||23.90||23.54||23.39|
|Support 3 (S3)||23.07||23.53||23.31|
|Support 4 (S4)||23.08|